– Recent data demonstrating reductions in seizure frequency and improvements in cognition and behavior support the potential for STK-001 as a disease-modifying potential medicine for the treatment.
Stoke Therapeutics reported its fourth-quarter financial results and announced Phase 1/2a end of study data after the bell Monday. The company reported quarterly losses of 60 cents per share which beat the analyst consensus estimate of 63 cents per share by 4.76%. Quarterly sales came in at $2.8 million which missed the analyst consensus estimate of $3.25 million by 13.82% and is a 14.32% decrease over sales of $3.27 million from the same period last year.
– Phase 1/2a End of Study Data: 70mg doses demonstrated substantial and sustained reductions in convulsive seizure frequency on top of the best available anti-seizure medicines; Median reductions.
Stoke Therapeutics Announces Landmark New Data That Support the Potential for STK-001 to be the First Disease-Modifying Medicine for the Treatment of Patients with Dravet Syndrome streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.